Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma
Plain-language summary
This trial is testing allogeneic stem cell transplant (from a donor) for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Selinexor, azacitidine (DRUG): For patients with NK/T-cell lymphoma, maintenance therapy with selinexor combined with azacitidine was initiated 60-90 days after allogeneic hematopoietic stem cell transplantation. The specific treatment regimen was as follows: Selinexor 40 mg once a week; if the blood routine was intolerable (i.e., PLT ≤ 50×109/L), 20 mg once a week could be used. Azacitidine 16 mg/m2/d, days 1-5. A 28-day treatment cycle was adopted, and the treatment was continued for 2 years.
Selinexor, azacitidine
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details